Loading…
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcri...
Saved in:
Published in: | Clinical cancer research 2021-09, Vol.27 (17), p.4768-4780 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3 |
---|---|
cites | cdi_FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3 |
container_end_page | 4780 |
container_issue | 17 |
container_start_page | 4768 |
container_title | Clinical cancer research |
container_volume | 27 |
creator | Marisa, Laetitia Blum, Yuna Taieb, Julien Ayadi, Mira Pilati, Camilla Le Malicot, Karine Lepage, Côme Salazar, Ramon Aust, Daniela Duval, Alex Blons, Hélène Taly, Valérie Gentien, David Rapinat, Audrey Selves, Janick Mouillet-Richard, Sophie Boige, Valérie Emile, Jean-François de Reyniès, Aurélien Laurent-Puig, Pierre |
description | The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications.
We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%.
Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12-1.59), 1.40, 95% CI (1.14-1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells.
This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine. |
doi_str_mv | 10.1158/1078-0432.ccr-21-0529 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8974433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2545607847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3</originalsourceid><addsrcrecordid>eNpdkVtr3DAQhUVJaS7tT2jRY_rgRHfZL4Fg0u7Chi69PAutPE4UbGkraQPJr6_NJiHNkwbNOWeY-RD6TMkZpbI-p0TXFRGcnTmXKkYrIlnzDh1RKXXFmZIHU_2sOUTHOd8RQgUl4gM65IKqmgh9hNbLUJItuzEm3F7_wgsokOINBPDlAS_HrXUl47UtHkLB66kVYvYZ-4BX0dnBP0KH2zjEgFsbHKSP6H1vhwyfnt4T9Ofb1e92Ua1-fF-2l6vKSUpLtRHgFK2lrVXPnSScwEY3TvcNI03PO6F6zTnZsB46zYGphkCnCO1qy0D0lp-gi33udrcZoXMw7zGYbfKjTQ8mWm_-7wR_a27ivakbLQTnU8DXfcDtG9vicmXmP8JZzbhQ93TSnj4NS_HvDnIxo88OhsEGiLtsmBRSTccWepLKvdSlmHOC_iWbEjOTMzMVM1MxbfvTMGpmcpPvy-t9XlzPqPg_jV-VMA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545607847</pqid></control><display><type>article</type><title>Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer</title><source>Freely Accessible Science Journals</source><creator>Marisa, Laetitia ; Blum, Yuna ; Taieb, Julien ; Ayadi, Mira ; Pilati, Camilla ; Le Malicot, Karine ; Lepage, Côme ; Salazar, Ramon ; Aust, Daniela ; Duval, Alex ; Blons, Hélène ; Taly, Valérie ; Gentien, David ; Rapinat, Audrey ; Selves, Janick ; Mouillet-Richard, Sophie ; Boige, Valérie ; Emile, Jean-François ; de Reyniès, Aurélien ; Laurent-Puig, Pierre</creator><creatorcontrib>Marisa, Laetitia ; Blum, Yuna ; Taieb, Julien ; Ayadi, Mira ; Pilati, Camilla ; Le Malicot, Karine ; Lepage, Côme ; Salazar, Ramon ; Aust, Daniela ; Duval, Alex ; Blons, Hélène ; Taly, Valérie ; Gentien, David ; Rapinat, Audrey ; Selves, Janick ; Mouillet-Richard, Sophie ; Boige, Valérie ; Emile, Jean-François ; de Reyniès, Aurélien ; Laurent-Puig, Pierre</creatorcontrib><description>The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications.
We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%.
Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12-1.59), 1.40, 95% CI (1.14-1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells.
This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-21-0529</identifier><identifier>PMID: 34168047</identifier><language>eng</language><publisher>United States: American Association for Cancer Research</publisher><subject>Aged ; Cancer ; Cell Line, Tumor ; Colonic Neoplasms - classification ; Colonic Neoplasms - genetics ; Colonic Neoplasms - mortality ; Colonic Neoplasms - pathology ; Female ; Gene Expression Profiling ; Humans ; Life Sciences ; Male ; Precision Medicine and Imaging ; Prognosis ; Survival Rate ; Tumor Microenvironment</subject><ispartof>Clinical cancer research, 2021-09, Vol.27 (17), p.4768-4780</ispartof><rights>2021 The Authors; Published by the American Association for Cancer Research.</rights><rights>Attribution - NonCommercial - NoDerivatives</rights><rights>2021 The Authors; Published by the American Association for Cancer Research 2021 American Association for Cancer Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3</citedby><cites>FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3</cites><orcidid>0000-0002-6073-4466 ; 0000-0001-9419-6232 ; 0000-0002-3226-8525 ; 0000-0002-9955-4753 ; 0000-0002-1781-5180 ; 0000-0002-4019-2858 ; 0000-0001-8475-5459 ; 0000-0003-1534-1724 ; 0000-0002-4716-8017 ; 0000-0001-8317-5188 ; 0000-0002-7817-4663 ; 0000-0002-0572-8426 ; 0000-0002-8950-1949 ; 0000-0002-3116-8602</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34168047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03282346$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Marisa, Laetitia</creatorcontrib><creatorcontrib>Blum, Yuna</creatorcontrib><creatorcontrib>Taieb, Julien</creatorcontrib><creatorcontrib>Ayadi, Mira</creatorcontrib><creatorcontrib>Pilati, Camilla</creatorcontrib><creatorcontrib>Le Malicot, Karine</creatorcontrib><creatorcontrib>Lepage, Côme</creatorcontrib><creatorcontrib>Salazar, Ramon</creatorcontrib><creatorcontrib>Aust, Daniela</creatorcontrib><creatorcontrib>Duval, Alex</creatorcontrib><creatorcontrib>Blons, Hélène</creatorcontrib><creatorcontrib>Taly, Valérie</creatorcontrib><creatorcontrib>Gentien, David</creatorcontrib><creatorcontrib>Rapinat, Audrey</creatorcontrib><creatorcontrib>Selves, Janick</creatorcontrib><creatorcontrib>Mouillet-Richard, Sophie</creatorcontrib><creatorcontrib>Boige, Valérie</creatorcontrib><creatorcontrib>Emile, Jean-François</creatorcontrib><creatorcontrib>de Reyniès, Aurélien</creatorcontrib><creatorcontrib>Laurent-Puig, Pierre</creatorcontrib><title>Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications.
We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%.
Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12-1.59), 1.40, 95% CI (1.14-1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells.
This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine.</description><subject>Aged</subject><subject>Cancer</subject><subject>Cell Line, Tumor</subject><subject>Colonic Neoplasms - classification</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - mortality</subject><subject>Colonic Neoplasms - pathology</subject><subject>Female</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Precision Medicine and Imaging</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Tumor Microenvironment</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkVtr3DAQhUVJaS7tT2jRY_rgRHfZL4Fg0u7Chi69PAutPE4UbGkraQPJr6_NJiHNkwbNOWeY-RD6TMkZpbI-p0TXFRGcnTmXKkYrIlnzDh1RKXXFmZIHU_2sOUTHOd8RQgUl4gM65IKqmgh9hNbLUJItuzEm3F7_wgsokOINBPDlAS_HrXUl47UtHkLB66kVYvYZ-4BX0dnBP0KH2zjEgFsbHKSP6H1vhwyfnt4T9Ofb1e92Ua1-fF-2l6vKSUpLtRHgFK2lrVXPnSScwEY3TvcNI03PO6F6zTnZsB46zYGphkCnCO1qy0D0lp-gi33udrcZoXMw7zGYbfKjTQ8mWm_-7wR_a27ivakbLQTnU8DXfcDtG9vicmXmP8JZzbhQ93TSnj4NS_HvDnIxo88OhsEGiLtsmBRSTccWepLKvdSlmHOC_iWbEjOTMzMVM1MxbfvTMGpmcpPvy-t9XlzPqPg_jV-VMA</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Marisa, Laetitia</creator><creator>Blum, Yuna</creator><creator>Taieb, Julien</creator><creator>Ayadi, Mira</creator><creator>Pilati, Camilla</creator><creator>Le Malicot, Karine</creator><creator>Lepage, Côme</creator><creator>Salazar, Ramon</creator><creator>Aust, Daniela</creator><creator>Duval, Alex</creator><creator>Blons, Hélène</creator><creator>Taly, Valérie</creator><creator>Gentien, David</creator><creator>Rapinat, Audrey</creator><creator>Selves, Janick</creator><creator>Mouillet-Richard, Sophie</creator><creator>Boige, Valérie</creator><creator>Emile, Jean-François</creator><creator>de Reyniès, Aurélien</creator><creator>Laurent-Puig, Pierre</creator><general>American Association for Cancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6073-4466</orcidid><orcidid>https://orcid.org/0000-0001-9419-6232</orcidid><orcidid>https://orcid.org/0000-0002-3226-8525</orcidid><orcidid>https://orcid.org/0000-0002-9955-4753</orcidid><orcidid>https://orcid.org/0000-0002-1781-5180</orcidid><orcidid>https://orcid.org/0000-0002-4019-2858</orcidid><orcidid>https://orcid.org/0000-0001-8475-5459</orcidid><orcidid>https://orcid.org/0000-0003-1534-1724</orcidid><orcidid>https://orcid.org/0000-0002-4716-8017</orcidid><orcidid>https://orcid.org/0000-0001-8317-5188</orcidid><orcidid>https://orcid.org/0000-0002-7817-4663</orcidid><orcidid>https://orcid.org/0000-0002-0572-8426</orcidid><orcidid>https://orcid.org/0000-0002-8950-1949</orcidid><orcidid>https://orcid.org/0000-0002-3116-8602</orcidid></search><sort><creationdate>20210901</creationdate><title>Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer</title><author>Marisa, Laetitia ; Blum, Yuna ; Taieb, Julien ; Ayadi, Mira ; Pilati, Camilla ; Le Malicot, Karine ; Lepage, Côme ; Salazar, Ramon ; Aust, Daniela ; Duval, Alex ; Blons, Hélène ; Taly, Valérie ; Gentien, David ; Rapinat, Audrey ; Selves, Janick ; Mouillet-Richard, Sophie ; Boige, Valérie ; Emile, Jean-François ; de Reyniès, Aurélien ; Laurent-Puig, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Cancer</topic><topic>Cell Line, Tumor</topic><topic>Colonic Neoplasms - classification</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - mortality</topic><topic>Colonic Neoplasms - pathology</topic><topic>Female</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Precision Medicine and Imaging</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Tumor Microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marisa, Laetitia</creatorcontrib><creatorcontrib>Blum, Yuna</creatorcontrib><creatorcontrib>Taieb, Julien</creatorcontrib><creatorcontrib>Ayadi, Mira</creatorcontrib><creatorcontrib>Pilati, Camilla</creatorcontrib><creatorcontrib>Le Malicot, Karine</creatorcontrib><creatorcontrib>Lepage, Côme</creatorcontrib><creatorcontrib>Salazar, Ramon</creatorcontrib><creatorcontrib>Aust, Daniela</creatorcontrib><creatorcontrib>Duval, Alex</creatorcontrib><creatorcontrib>Blons, Hélène</creatorcontrib><creatorcontrib>Taly, Valérie</creatorcontrib><creatorcontrib>Gentien, David</creatorcontrib><creatorcontrib>Rapinat, Audrey</creatorcontrib><creatorcontrib>Selves, Janick</creatorcontrib><creatorcontrib>Mouillet-Richard, Sophie</creatorcontrib><creatorcontrib>Boige, Valérie</creatorcontrib><creatorcontrib>Emile, Jean-François</creatorcontrib><creatorcontrib>de Reyniès, Aurélien</creatorcontrib><creatorcontrib>Laurent-Puig, Pierre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marisa, Laetitia</au><au>Blum, Yuna</au><au>Taieb, Julien</au><au>Ayadi, Mira</au><au>Pilati, Camilla</au><au>Le Malicot, Karine</au><au>Lepage, Côme</au><au>Salazar, Ramon</au><au>Aust, Daniela</au><au>Duval, Alex</au><au>Blons, Hélène</au><au>Taly, Valérie</au><au>Gentien, David</au><au>Rapinat, Audrey</au><au>Selves, Janick</au><au>Mouillet-Richard, Sophie</au><au>Boige, Valérie</au><au>Emile, Jean-François</au><au>de Reyniès, Aurélien</au><au>Laurent-Puig, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>27</volume><issue>17</issue><spage>4768</spage><epage>4780</epage><pages>4768-4780</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>The consensus molecular subtypes (CMS) represent a significant advance in the understanding of intertumor heterogeneity in colon cancer. Intratumor heterogeneity (ITH) is the new frontier for refining prognostication and understanding treatment resistance. This study aims at deciphering the transcriptomic ITH of colon cancer and understanding its potential prognostic implications.
We deconvoluted the transcriptomic profiles of 1,779 tumors from the PETACC8 trial and 155 colon cancer cell lines as weighted sums of the four CMSs, using the Weighted In Silico Pathology (WISP) algorithm. We assigned to each tumor and cell line a combination of up to three CMS subtypes with a threshold above 20%.
Over 55% of tumors corresponded to mixtures of at least two CMSs, demonstrating pervasive ITH in colon cancer. Of note, ITH was associated with shorter disease-free survival (DFS) and overall survival, [HR, 1.34; 95% confidence interval (CI; 1.12-1.59), 1.40, 95% CI (1.14-1.71), respectively]. Moreover, we uncovered specific combinations of CMS associated with dismal prognosis. In multivariate analysis, ITH represents the third parameter explaining DFS variance, after T and N stages. At a cellular level, combined WISP and single-cell transcriptomic analysis revealed that most colon cancer cell lines are a mixture of cells falling into different CMSs, indicating that ITH may correspond to distinct functional statuses of colon cancer cells.
This study shows that CMS-based transcriptomic ITH is frequent in colon cancer and impacts its prognosis. CMS-based transcriptomic ITH may correspond to distinct functional statuses of colon cancer cells, suggesting plasticity between CMS-related cell populations. Transcriptomic ITH deserves further assessment in the context of personalized medicine.</abstract><cop>United States</cop><pub>American Association for Cancer Research</pub><pmid>34168047</pmid><doi>10.1158/1078-0432.ccr-21-0529</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-6073-4466</orcidid><orcidid>https://orcid.org/0000-0001-9419-6232</orcidid><orcidid>https://orcid.org/0000-0002-3226-8525</orcidid><orcidid>https://orcid.org/0000-0002-9955-4753</orcidid><orcidid>https://orcid.org/0000-0002-1781-5180</orcidid><orcidid>https://orcid.org/0000-0002-4019-2858</orcidid><orcidid>https://orcid.org/0000-0001-8475-5459</orcidid><orcidid>https://orcid.org/0000-0003-1534-1724</orcidid><orcidid>https://orcid.org/0000-0002-4716-8017</orcidid><orcidid>https://orcid.org/0000-0001-8317-5188</orcidid><orcidid>https://orcid.org/0000-0002-7817-4663</orcidid><orcidid>https://orcid.org/0000-0002-0572-8426</orcidid><orcidid>https://orcid.org/0000-0002-8950-1949</orcidid><orcidid>https://orcid.org/0000-0002-3116-8602</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1078-0432 |
ispartof | Clinical cancer research, 2021-09, Vol.27 (17), p.4768-4780 |
issn | 1078-0432 1557-3265 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8974433 |
source | Freely Accessible Science Journals |
subjects | Aged Cancer Cell Line, Tumor Colonic Neoplasms - classification Colonic Neoplasms - genetics Colonic Neoplasms - mortality Colonic Neoplasms - pathology Female Gene Expression Profiling Humans Life Sciences Male Precision Medicine and Imaging Prognosis Survival Rate Tumor Microenvironment |
title | Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intratumor%20CMS%20Heterogeneity%20Impacts%20Patient%20Prognosis%20in%20Localized%20Colon%20Cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=Marisa,%20Laetitia&rft.date=2021-09-01&rft.volume=27&rft.issue=17&rft.spage=4768&rft.epage=4780&rft.pages=4768-4780&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.ccr-21-0529&rft_dat=%3Cproquest_pubme%3E2545607847%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c511t-b4ec6185a86f3c5030eb79c7f9209f3d46f7330b2fed73e2690ed601d8a2e4fa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2545607847&rft_id=info:pmid/34168047&rfr_iscdi=true |